Next |
home / stock / nnvc / nnvc message board
Subject | By | Source | When |
---|---|---|---|
Companys Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness | drkazmd65 | investorshub | 07/11/2023 2:43:07 PM |
We're up almost to $1.60 (it was briefly | drkazmd65 | investorshub | 07/11/2023 2:36:58 PM |
Thanks for the thoughts. | loanranger | investorshub | 07/10/2023 9:33:09 PM |
It's impossible to know the exact details of | KMBJN | investorshub | 07/10/2023 4:37:50 PM |
what does this mean? | arvitar | investorshub | 07/10/2023 11:56:22 AM |
I guess this news explains your return from | loanranger | investorshub | 07/08/2023 9:24:42 PM |
$NNVC Thoughts on where this is headed? | loanranger | investorshub | 07/08/2023 4:31:18 PM |
It's Phase I. Your start with relatively | mike41 | investorshub | 07/08/2023 3:46:31 PM |
$NNVC Have a look at this | KMBJN | investorshub | 07/06/2023 10:11:52 PM |
Just a few questions based on some of | loanranger | investorshub | 07/06/2023 3:27:29 PM |
Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is | drkazmd65 | investorshub | 07/06/2023 1:14:35 PM |
Well said Sir! | drkazmd65 | investorshub | 06/30/2023 7:17:03 PM |
$NNVC has indeed received IND approval in India | KMBJN | investorshub | 06/30/2023 6:37:22 PM |
https://investorshub.advfn.com/boards/read msg.aspx?message id=171653027 | arvitar | investorshub | 06/30/2023 6:19:36 PM |
Good lord. | arvitar | investorshub | 06/30/2023 6:17:17 PM |
What you said Sir! | drkazmd65 | investorshub | 06/30/2023 2:59:10 PM |
If I had to guess, I imagine they | KMBJN | investorshub | 06/30/2023 2:56:20 PM |
Not completely worthless though. Mostly a Phase | drkazmd65 | investorshub | 06/30/2023 2:19:33 PM |
$NNVC Price trading last up | KMBJN | investorshub | 06/30/2023 2:13:55 PM |
"And as such, virtually worthless." | loanranger | investorshub | 06/30/2023 1:38:46 AM |
News, Short Squeeze, Breakout and More Instantly...
SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending December 31, 2023 with the Securi...
SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, explains that the demonstration of strong safety and tolerability of NV-CoV-2 o...
SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the healthy subjects part of the Phase 1a/1b Clinical Trial...